Lilly obesity drug Mounjaro to be offered in Britain's NHS after watchdog nod
Portfolio Pulse from
Eli Lilly's obesity drug Mounjaro has been approved by the UK's NICE for use in the NHS, making it available to some patients starting March.
December 23, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's obesity drug Mounjaro has been approved by the UK's NICE for use in the NHS, making it available to some patients starting March.
The approval of Mounjaro by NICE for use in the NHS is a significant regulatory milestone for Eli Lilly, potentially increasing the drug's market reach and sales. This positive development is likely to boost investor sentiment and positively impact Eli Lilly's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90